Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Simcere Pharmaceutical GroupSTU:S2P -3.17%91 EV-to-OCF is 11.93 as of Sep. 08, 2026, which is 29% below its 10-year median of 16.86. GuruFocus rates STU:S2P with a GF Score™ of 91/100 and a GF Value™ of €1.18 (Fairly Valued). Among 1,007 Drug Manufacturers companies, Simcere Pharmaceutical Group ranks worse than 55.41% on this metric.
The historical rank and industry rank for Simcere Pharmaceutical Group's EV-to-OCF or its related term are showing as below:
STU:S2P'
s EV-to-OCF Range Over the Past 10 Years
Min: -124.55 Med: 16.86 Max: 315.93
Current: 11.95
During the past 9 years, the highest EV-to-OCF of Simcere Pharmaceutical Group was 315.93. The lowest was -124.55. And the median was 16.86.
STU:S2P's EV-to-OCF is ranked worse than 55.41% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 10.53
vs STU:S2P: 11.95
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Simcere Pharmaceutical Group (STU:S2P) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Simcere Pharmaceutical Group's PE Ratio (TTM) for today is calculated as:
Simcere Pharmaceutical Group's share price for today is €1.22.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Simcere Pharmaceutical Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.076.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Simcere Pharmaceutical Group EV-to-OCF Related Terms
Simcere Pharmaceutical Group EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Simcere Pharmaceutical Group's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Simcere Pharmaceutical Group EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Simcere Pharmaceutical Group's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Simcere Pharmaceutical Group's EV-to-OCF falls into.
Simcere Pharmaceutical Group's current Enterprise Value is €2,906 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Simcere Pharmaceutical Group's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €244 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Simcere Pharmaceutical Group (STU:S2P) has a EV-to-OCF of 11.93 as of Sep. 08, 2026. This is 29% below median its historical median of 16.86. According to the industry distribution chart, Simcere Pharmaceutical Group ranks #558 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 55.4%.
Is Simcere Pharmaceutical Group's EV-to-OCF too high?
Simcere Pharmaceutical Group's current EV-to-OCF of 11.93 is 29% below median its 10-year median of 16.86. The Drug Manufacturers industry median EV-to-OCF is 10.53. Simcere Pharmaceutical Group's value of 11.93 is 13.3% above this industry median. Based on the distribution chart, Simcere Pharmaceutical Group ranks #558 out of 1007 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Simcere Pharmaceutical Group has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Simcere Pharmaceutical Group's EV-to-OCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Simcere Pharmaceutical Group ranks #558 out of 1007 companies for EV-to-OCF. This places Simcere Pharmaceutical Group in the lower half of its industry. The industry median EV-to-OCF is 10.53. Simcere Pharmaceutical Group's value of 11.93 is 13.3% above this benchmark. While the company's 10-year median is 16.86 vs. the industry median of 10.53, Simcere Pharmaceutical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.53, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Simcere Pharmaceutical Group's current EV-to-OCF of 11.93 is 13.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Simcere Pharmaceutical Group's current EV-to-OCF is 11.93, which is 29% below median its own 10-year median of 16.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simcere Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Simcere Pharmaceutical Group (STU:S2P) is currently considered Fairly Valued. The stock's GF Value™ is €1.18, compared to a current price of €1.22 — trading 3.4% above its estimated fair value. The current EV-to-OCF is 11.93, which is 29% below median its 10-year median of 16.86 and 13.3% above the Drug Manufacturers industry median of 10.53. Simcere Pharmaceutical Group's overall GF Score™ is 91/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Simcere Pharmaceutical Group (STU:S2P), the current EV-to-OCF is 11.93 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Simcere Pharmaceutical Group (STU:S2P) Overvalued in 2026?
Based on GuruFocus' analysis, Simcere Pharmaceutical Group stock appears to be overvalued.
The current stock price of €1.22 is trading 3.4% above its estimated GF Value™ of €1.18.
GuruFocus considers Simcere Pharmaceutical Group to be Fairly Valued.
Key valuation signals for STU:S2P:
EV-to-OCF: 11.93 (29% below median its 10-year median of 16.86)
GF Value™: €1.18 vs. price of €1.22 (3.4% above fair value)
Industry Position: 13.3% above the Drug Manufacturers median (#558 of 1007)
No single metric tells the full story. See the STU:S2P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. The company has a diversified product portfolio focused on therapeutic areas, including, neuroscience, anti-oncology, autoimmune, and antiinfection. The company's products include Endostar, Enweida, Enzeshu, Iremod, Quviviq, Cosela, Sanbexin and Others.
91GF Score
Get the complete analysis for STU:S2P
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:S2P has been successfully added to your 
